{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:51:44Z","timestamp":1779904304035,"version":"3.53.1"},"reference-count":150,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"publisher","award":["UMO-2020\/01\/0\/NZ6\/00137"],"award-info":[{"award-number":["UMO-2020\/01\/0\/NZ6\/00137"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Influenza virus has the potential for being one of the deadliest viruses, as we know from the pandemic\u2019s history. The influenza virus, with a constantly mutating genome, is becoming resistant to existing antiviral drugs and vaccines. For that reason, there is an urgent need for developing new therapeutics and therapies. Despite the fact that a new generation of universal vaccines or anti-influenza drugs are being developed, the perfect remedy has still not been found. In this review, various strategies for using nanoparticles (NPs) to defeat influenza virus infections are presented. Several categories of NP applications are highlighted: NPs as immuno-inducing vaccines, NPs used in gene silencing approaches, bare NPs influencing influenza virus life cycle and the use of NPs for drug delivery. This rapidly growing field of anti-influenza methods based on nanotechnology is very promising. Although profound research must be conducted to fully understand and control the potential side effects of the new generation of antivirals, the presented and discussed studies show that nanotechnology methods can effectively induce the immune responses or inhibit influenza virus activity both in vitro and in vivo. Moreover, with its variety of modification possibilities, nanotechnology has great potential for applications and may be helpful not only in anti-influenza but also in the general antiviral approaches.<\/jats:p>","DOI":"10.3390\/pathogens9121020","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:15:43Z","timestamp":1606994143000},"page":"1020","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anti-Influenza Strategies Based on Nanoparticle Applications"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-4220","authenticated-orcid":false,"given":"Klaudia","family":"Wieczorek","sequence":"first","affiliation":[{"name":"Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland"},{"name":"NanoBioMedical Centre, Adam Mickiewicz University, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7293-7183","authenticated-orcid":false,"given":"Barbara","family":"Szutkowska","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-003X","authenticated-orcid":false,"given":"Elzbieta","family":"Kierzek","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sdata.2018.17","article-title":"Epidemiological characteristics of human-infective RNA viruses","volume":"5","author":"Woolhouse","year":"2018","journal-title":"Sci. Data"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4049\/jimmunol.1801010","article-title":"Influenza Pathogenesis: The Effect of Host Factors on Severity of Disease","volume":"202","author":"Gounder","year":"2019","journal-title":"J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.coi.2011.07.016","article-title":"The pathogenesis of influenza virus infections: The contributions of virus and host factors","volume":"23","author":"Fukuyama","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza Virus: Dealing with a Drifting and Shifting Pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.1128\/JVI.01573-15","article-title":"Evolutionary Dynamics and Global Diversity of Influenza A Virus","volume":"89","author":"Rejmanek","year":"2015","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Shao, W., Li, X., Goraya, M.U., Wang, S., and Chen, J.L. (2017). Evolution of influenza a virus by mutation and re-assortment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081650"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17888-w","article-title":"Influenza A virus is transmissible via aerosolized fomites","volume":"11","author":"Asadi","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41385-020-0287-5","article-title":"Seasonal and pandemic influenza: 100 years of progress, still much to learn","volume":"13","author":"Dunning","year":"2020","journal-title":"Mucosal Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Saunders-Hastings, P.R., and Krewski, D. (2016). Reviewing the history of pandemic influenza: Understanding patterns of emergence and transmission. Pathogens, 5.","DOI":"10.3390\/pathogens5040066"},{"key":"ref_11","first-page":"1","article-title":"SARS-CoV-2 pandemic: An overview","volume":"77","author":"Martellucci","year":"2020","journal-title":"Adv. Biol. Regul."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Triggle, C.R., Bansal, D., Farag, E.A.B.A., Ding, H., and Sultan, A.A. (2020). COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. Am. Soc. Microbiol., 5.","DOI":"10.1128\/mSphere.00317-20"},{"key":"ref_13","unstructured":"Chang, T., Wu, J., and Chang, L. (2020). Co-infection of influenza B virus and SARS-CoV-2: A case report from Taiwan. J. Formos. Med. Assoc., 19\u201320."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hashemi, S.A., Safamanesh, S., Ghasemzadeh-moghaddam, H., Ghafouri, M., and Amir, A. (2020). High prevalence of SARS-CoV-2 and influenza A virus (H1N1) co-infection in dead patients in Northeastern Iran. J. Med. Virol., 1\u20135.","DOI":"10.1002\/jmv.26364"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kondo, Y., Miyazaki, S., Yamashita, R., and Ikeda, T. (2020). Coinfection with SARS-CoV-2 and influenza A virus. BMJ Case Rep., 13.","DOI":"10.1136\/bcr-2020-236812"},{"key":"ref_16","first-page":"e9852","article-title":"COVID-19 and Influenza Co-Infection: Report of Three Cases","volume":"12","author":"Singh","year":"2020","journal-title":"Cureus"},{"key":"ref_17","unstructured":"(2020, September 28). Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) How to Prevent Flu, Available online: https:\/\/www.cdc.gov\/flu\/prevent\/prevention.htm."},{"key":"ref_18","unstructured":"World Health Organization (2020, September 28). WHO Rcommendations on the Composition of Influenza Virus Vaccines. Available online: https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/en\/."},{"key":"ref_19","unstructured":"(2020, September 28). Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) Past Seasons Vaccine Effectiveness Estimates, Available online: https:\/\/www.cdc.gov\/flu\/vaccines-work\/past-seasons-estimates.html."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.48.1900604","article-title":"Low 2018\/19 vaccine effectiveness against influenza A(H3N2) among 15\u201364-year-olds in Europe: Exploration by birth cohort","volume":"24","author":"Kissling","year":"2019","journal-title":"Eurosurveillance"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1900121","DOI":"10.2807\/1560-7917.ES.2019.24.1900121","article-title":"Interim 2018\/19 influenza vaccine effectiveness: Six European studies, October 2018 to January 2019","volume":"24","author":"Kissling","year":"2019","journal-title":"Eurosurveillance"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4049\/jimmunol.1801054","article-title":"Development of a universal influenza vaccine","volume":"202","year":"2019","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1128\/AAC.03667-14","article-title":"Multiple influenza a (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient","volume":"58","author":"Eshaghi","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dobrovolny, H.M., and Beauchemin, C.A.A. (2017). Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180582"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/14656566.2019.1626824","article-title":"Neuraminidase inhibitors as a strategy for influenza treatment: Pros, cons and future perspectives","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7150\/thno.17071","article-title":"Progress of small molecular inhibitors in the development of anti-influenza virus agents","volume":"7","author":"Wu","year":"2017","journal-title":"Theranostics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3389\/fimmu.2018.01946","article-title":"Treating influenza infection, from now and into the future","volume":"9","author":"Davidson","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2217\/epi-2017-0170","article-title":"MiRNA-based strategy for modulation of influenza A virus infection","volume":"10","author":"Keshavarz","year":"2018","journal-title":"Epigenomics"},{"key":"ref_29","unstructured":"Bhagyaraj, S.M., and Oluwafemi, O.S. (2018). Synthesis of Inorganic Nanomaterials, Elsevier Ltd.. [1st ed.]."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lungu, M., Neculae, A., Bunoiu, M., and Biris, C. (2015). Nanoparticles\u2019 Promises and Risks, Springer Nature.","DOI":"10.1007\/978-3-319-11728-7"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1351\/PAC-REC-10-12-04","article-title":"Terminology for biorelated polymers applications (IUPACRecommendations, 2.0.1.2.)","volume":"84","author":"Vert","year":"2012","journal-title":"Pure Appl. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00018-011-0851-y","article-title":"Nanobiology-convergence of disciplines inspires great applications","volume":"69","author":"Kroll","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/biomedicines3030203","article-title":"Nanomaterials-tools, technology and methodology of nanotechnology based biomedical systems for diagnostics and therapy","volume":"3","author":"Schmidt","year":"2015","journal-title":"Biomedicines"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/acsmedchemlett.0c00075","article-title":"Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies","volume":"11","author":"Sanna","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.2147\/IJN.S137338","article-title":"Application of nanodiagnostics in point-of-care tests for infectious diseases","volume":"12","author":"Wang","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gamage, S., Howard, M., Makita, H., Cross, B., Hastings, G., Luo, M., and Abate, Y. (2018). Probing structural changes in single enveloped virus particles using nano-infrared spectroscopic imaging. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199112"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/btm2.10005","article-title":"Engineering nanoparticles to overcome barriers to immunotherapy","volume":"1","author":"Toy","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1039\/C0NR00646G","article-title":"Aptamer-conjugated nanomaterials for bioanalysis and biotechnology applications","volume":"3","author":"Chen","year":"2011","journal-title":"Nanoscale"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.2147\/IJN.S137222","article-title":"Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro","volume":"12","author":"Wang","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.nano.2018.03.007","article-title":"Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity","volume":"14","author":"Wang","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.4049\/jimmunol.1202654","article-title":"Immunization with Biodegradable Nanoparticles Efficiently Induces Cellular Immunity and Protects against Influenza Virus Infection","volume":"190","author":"Knuschke","year":"2013","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1016\/j.biomaterials.2010.03.067","article-title":"The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation","volume":"31","author":"Sokolova","year":"2010","journal-title":"Biomaterials"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1208\/s12249-013-0058-7","article-title":"Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine","volume":"15","author":"Sawaengsak","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"ref_47","first-page":"229","article-title":"Hemagglutinin-based polyanhydride nanovaccines against H5N1 infuenza elicit protective virus neutralizing titers and cell-mediated immunity","volume":"10","author":"Ross","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/acsbiomaterials.5b00477","article-title":"Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza","volume":"2","author":"Ross","year":"2016","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1016\/j.vaccine.2019.06.077","article-title":"Effective mosaic-based nanovaccines against avian influenza in poultry","volume":"37","author":"Chandrasekar","year":"2019","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2217\/nnm.13.58","article-title":"Gold nanoparticle\u2013M2e conjugate coformulated with CpG induces protective immunity against influenza A virus","volume":"9","author":"Tao","year":"2014","journal-title":"Nanomedicine (Lond.)"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.vaccine.2015.03.063","article-title":"M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection","volume":"33","author":"Tao","year":"2015","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2017.01.021","article-title":"Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses","volume":"141","author":"Tao","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_53","first-page":"2751","article-title":"Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles","volume":"10","author":"Yong","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.virol.2005.04.004","article-title":"Universal influenza A vaccine: Optimization of M2-based constructs","volume":"337","author":"Jou","year":"2005","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1016\/j.vaccine.2008.09.038","article-title":"Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies","volume":"26","author":"Martens","year":"2008","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/jmv.24253","article-title":"Conjugating Influenza A (H1N1) Antigen to N-Trimethylaminoethylmethacrylate Chitosan Nanoparticles Improves the Immunogenicity of the Antigen After Nasal Administration","volume":"87","author":"Liu","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hu, C.M.J., Chien, C.Y., Liu, M.T., Fang, Z.S., Chang, S.Y., Juang, R.H., Chang, S.C., and Chen, H.W. (2017). Multi-antigen avian influenza a (H7N9) virus-like particles: Particulate characterizations and immunogenicity evaluation in murine and avian models. BMC Biotechnol., 17.","DOI":"10.1186\/s12896-016-0321-6"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1039\/C8BM01443D","article-title":"Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice","volume":"7","author":"Ross","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hiremath, J., Kang, K.I., Xia, M., Elaish, M., Binjawadagi, B., Ouyang, K., Dhakal, S., Arcos, J., Torrelles, J.B., and Jiang, X. (2016). Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151922"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s12272-013-0043-4","article-title":"Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization","volume":"36","author":"Dehghan","year":"2013","journal-title":"Arch. Pharm. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.08.032","article-title":"Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants","volume":"475","author":"Dehghan","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.vaccine.2017.01.019","article-title":"Polyanhydride nanovaccine against swine influenza virus in pigs","volume":"35","author":"Dhakal","year":"2017","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1016\/j.vaccine.2017.07.016","article-title":"Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice","volume":"35","author":"Hurst","year":"2017","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Alkie, T.N., Yitbarek, A., Taha-Abdelaziz, K., Astill, J., and Sharif, S. (2018). Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206324"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Magini, D., Giovani, C., Mangiavacchi, S., MacCari, S., Cecchi, R., Ulmer, J.B., De Gregorio, E., Geall, A.J., Brazzoli, M., and Bertholet, S. (2016). Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161193"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-61779-621-0_9","article-title":"Influenza Virus Surveillance, Vaccine Strain Selection, and Manufacture","volume":"865","author":"Bucher","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing\u2014An overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"ref_71","first-page":"473","article-title":"Recommended composition of influenza virus vaccines for use in the 2020 southern hemisphere influenza season","volume":"94","author":"Global","year":"2019","journal-title":"Wkly. Epidemiol. Rec."},{"key":"ref_72","unstructured":"World Health Organization (2020, September 28). Recommended Composition of Influenza Virus Vaccines for Use in the 2018\u20132019 Northern Hemisphere Influenza Season. Available online: https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/201802_recommendation.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hollingsworth, R., El Guerche-S\u00e9blain, C., Tsai, T., Vasiliev, Y., Lee, S., Bright, H., and Barbosa, P. (2020). Assessment of the benefits of seasonal influenza vaccination: Elements of a framework to interpret estimates of vaccine effectiveness estimates and support robust decision-making and communication. Influenza Other Respir. Viruses.","DOI":"10.1111\/irv.12786"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3389\/fimmu.2019.01677","article-title":"Protective antibodies against influenza proteins","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kosik, I., and Yewdell, J.W. (2019). Influenza hemagglutinin and neuraminidase: Yin\u2013yang proteins coevolving to thwart immunity. Viruses, 11.","DOI":"10.3390\/v11040346"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0966-842X(99)01460-2","article-title":"Understanding influenza virus pathogenicity Septic shock caused by Gram-positive bacteria","volume":"7","author":"Garten","year":"1999","journal-title":"Trends Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1039\/b517734k","article-title":"Influenza virus proton channels","volume":"5","author":"Pinto","year":"2006","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Manzoor, R., Igarashi, M., and Takada, A. (2017). Influenza A virus M2 protein: Roles from ingress to egress. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122649"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/jvi.62.8.2762-2772.1988","article-title":"Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions","volume":"62","author":"Zebedee","year":"1988","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2008.01.017","article-title":"Design and optimization of a multiplex anti-influenza peptide immunoassay","volume":"334","author":"Drummond","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.vetmic.2007.07.009","article-title":"The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure","volume":"126","author":"Kitikoon","year":"2008","journal-title":"Vet. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2018.03.024","article-title":"Vaccine options for influenza: Thinking small","volume":"53","author":"Schepens","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0572-3","article-title":"M2e-based universal influenza vaccines: A historical overview and new approaches to development","volume":"26","author":"Mezhenskaya","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Vasou, A., Sultanoglu, N., Goodbourn, S., Randall, R.E., and Kostrikis, L.G. (2017). Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: From synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses, 9.","DOI":"10.3390\/v9070186"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.vaccine.2009.03.034","article-title":"Inflammasome-activating nanoparticles as modulac systems for optimizing vaccine efficacy","volume":"27","author":"Demento","year":"2010","journal-title":"Vaccine"},{"key":"ref_86","first-page":"564","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.omtn.2019.12.018","article-title":"RNA Secondary Structure Motifs of the Influenza A Virus as Targets for siRNA-Mediated RNA Interference","volume":"19","author":"Piasecka","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Huang, D.T.-N., Lu, C.-Y., Shao, P.-L., Chang, L.-Y., Wang, J.-Y., Chang, Y.-H., Lai, M.-J., Chi, Y.-H., and Huang, L.-M. (2017). In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174523"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/acs.bioconjchem.9b00039","article-title":"A Short Chemically Modified dsRNA-Binding PNA (dbPNA) Inhibits Influenza Viral Replication by Targeting Viral RNA Panhandle Structure","volume":"30","author":"Kesy","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/nat.2016.0619","article-title":"Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication","volume":"26","author":"Lenartowicz","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41598-019-40443-7","article-title":"Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides","volume":"9","author":"Michalak","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/oli.2005.15.12","article-title":"Transfection protocol for antisense oligonucleotides affects uniformity of transfection in cell culture and efficiency of mRNA target reduction","volume":"15","author":"Reed","year":"2005","journal-title":"Oligonucleotides"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1529\/biophysj.104.048975","article-title":"Effect of cell electroporation on the conductivity of a cell suspension","volume":"88","author":"Pavlin","year":"2005","journal-title":"Biophys. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s00216-010-3821-6","article-title":"Mammalian cell transfection: The present and the future","volume":"397","author":"Kim","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/molecules16021271","article-title":"Oligomeric nucleic acids as antivirals","volume":"16","author":"Mescalchin","year":"2011","journal-title":"Molecules"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense Oligonucleotide Therapies:The Promise and the Challenges from a Toxicologic Pathologist\u2019s Perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/srep00756","article-title":"High-performance method for specific effect on nucleic acids in cells using TiO2~DNA nanocomposites","volume":"2","author":"Levina","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1134\/S1068162014020095","article-title":"Efficient inhibition of human influenza a virus by oligonucleotides electrostatically fixed on polylysine-containing TiO2 nanoparticles","volume":"40","author":"Levina","year":"2014","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijantimicag.2015.03.004","article-title":"Knockdown of different influenza A virus subtypes in cell culture by a single antisense oligodeoxyribonucleotide","volume":"46","author":"Levina","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3762\/bjnano.7.108","article-title":"High antiviral effect of TiO2\u00b7PL-DNA nanocomposites targeted to conservative regions of (-)RNA and (+)RNA of influenza A virus in cell culture","volume":"7","author":"Levina","year":"2016","journal-title":"Beilstein J. Nanotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1134\/S1068162015020028","article-title":"Composites of peptide nucleic acids with titanium dioxide nanoparticles. IV. Antiviral activity of nanocomposites containing DNA\/PNA duplexes","volume":"41","author":"Amirkhanov","year":"2015","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3762\/bjnano.9.234","article-title":"Non-agglomerated silicon-organic nanoparticles and their nanocomplexes with oligonucleotides: Synthesis and properties","volume":"9","author":"Levina","year":"2018","journal-title":"Beilstein J. Nanotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.nano.2017.08.001","article-title":"Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation","volume":"13","author":"Frede","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13346-017-0426-z","article-title":"Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA","volume":"8","author":"Jamali","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijantimicag.2017.01.026","article-title":"Efficient inhibition of influenza A viral replication in cells by deoxyribozymes delivered by nanocomposites","volume":"49","author":"Repkova","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coi.2018.06.010","article-title":"Antiviral RNA interference in mammals","volume":"54","author":"Ding","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1976","DOI":"10.1002\/rmv.1976","article-title":"A review on current status of antiviral siRNA","volume":"28","author":"Qureshi","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Brandelli, A., Ritter, A.C., and Veras, F.F. (2017). Antimicrobial Activities of Metal Nanoparticles. Metal Nanoparticles in Pharma, Springer.","DOI":"10.1007\/978-3-319-63790-7_15"},{"key":"ref_109","first-page":"88","article-title":"In vitro antiviral effect of \u201cnanosilver\u201d on influenza virus","volume":"17","author":"Mehrbod","year":"2009","journal-title":"Daru"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jviromet.2011.09.003","article-title":"Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro","volume":"178","author":"Xiang","year":"2011","journal-title":"J. Virol. Methods"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.2147\/IJN.S53622","article-title":"Inhibition of A\/Human\/Hubei\/3\/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo","volume":"8","author":"Xiang","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1556-276X-8-93","article-title":"Antiviral activity of silver nanoparticle\/chitosan composites against H1N1 influenza A virus","volume":"8","author":"Mori","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4014\/jmb.1508.08024","article-title":"In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza a virus","volume":"26","author":"Fatima","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jphotobiol.2018.08.013","article-title":"Ultra-sonication-assisted silver nanoparticles using Panax ginseng root extract and their anti-cancer and antiviral activities","volume":"188","author":"Sreekanth","year":"2018","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1128\/JVI.03256-13","article-title":"Surfactant-Modified Nanoclay Exhibits an Antiviral Activity with High Potency and Broad Spectrum","volume":"88","author":"Liang","year":"2014","journal-title":"J. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13409","DOI":"10.1039\/c3ra47542e","article-title":"An in vitro analysis of H1N1 viral inhibition using polymer coated superparamagnetic Fe3O4 nanoparticles","volume":"4","author":"Kumar","year":"2014","journal-title":"RSC Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jiac.2018.12.006","article-title":"Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus","volume":"25","author":"Kumar","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0563-4","article-title":"Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: Another emerging application of nanomedicine","volume":"26","author":"Ghaffari","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1039\/c0md00229a","article-title":"Effective multi-strain inhibition of influenza virus by anionic gold nanoparticles","volume":"2","author":"Sametband","year":"2011","journal-title":"Med. Chem. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1002\/smll.201001349","article-title":"Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles","volume":"6","author":"Papp","year":"2010","journal-title":"Small"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1751-1097.2010.00763.x","article-title":"Photocatalytic inactivation efficiency of anatase nano-TiO2 sol on the H9N2 avian influenza virus","volume":"86","author":"Cui","year":"2010","journal-title":"Photochem. Photobiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1292\/jvms.14-0158","article-title":"Inactivation of avian influenza virus, Newcastle disease virus and goose parvovirus using solution of nano-sized scallop shell powder","volume":"76","author":"Thammakarn","year":"2014","journal-title":"J. Vet. Med. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2147\/IJN.S221667","article-title":"Pre-treatment with zirconia nanoparticles reduces inflammation induced by the pathogenic H5N1 influenza virus","volume":"15","author":"Huo","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.7150\/thno.35826","article-title":"Catalytic inactivation of influenza virus by iron oxide nanozyme","volume":"9","author":"Qin","year":"2019","journal-title":"Theranostics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/infdis\/159.3.430","article-title":"Resistance of influenza A virus to amantadine and rimantadine: Results of the one decade of surveillance","volume":"159","author":"Belshe","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_126","unstructured":"(2020, September 28). Influenza (Flu) Antiviral Drugs and Related Information\u2014Get Information on Medicines for the Flu, Available online: https:\/\/www.fda.gov\/drugs\/information-drug-class\/influenza-flu-antiviral-drugs-and-related-information."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1506.081357","article-title":"Oseltamivir-and amantadine-resistant influenza viruses A (H1N1)","volume":"15","author":"Cheng","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/JCM.01532-09","article-title":"Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A\/H1N1 viruses","volume":"48","author":"Zaraket","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1128\/AAC.49.11.4515-4520.2005","article-title":"Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors","volume":"49","author":"Mishin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"131440","DOI":"10.1016\/j.tet.2020.131440","article-title":"The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle?","volume":"76","author":"Sagandira","year":"2020","journal-title":"Tetrahedron"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1016\/j.bmcl.2018.10.040","article-title":"Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors","volume":"28","author":"Cheng","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_132","unstructured":"European Medicines Agency (2020, September 28). Alpivab (Peramivir). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alpivab."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ison, M.G., and Hayden, F.G. (2017). Antiviral Agents Against Respiratory Viruses, Elsevier Ltd.. [4th ed.].","DOI":"10.1016\/B978-0-7020-6285-8.00154-4"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: First Global Approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: The new influenza drug on the market","volume":"35","author":"Shaw","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.2147\/IJN.S140939","article-title":"Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus","volume":"12","author":"Li","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"35290","DOI":"10.1039\/C7RA06477B","article-title":"Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with zanamivir through p38 and JNK signaling pathways","volume":"7","author":"Lin","year":"2017","journal-title":"RSC Adv."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/IJN.S155994","article-title":"Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways","volume":"13","author":"Li","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.2147\/IJN.S177658","article-title":"Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway","volume":"13","author":"Lin","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1039\/C9TB00531E","article-title":"Inhibition of H1N1 influenza virus-induced apoptosis by selenium nanoparticles functionalized with arbidol through ROS-mediated signaling pathways","volume":"7","author":"Li","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"89679","DOI":"10.1039\/C6RA18493F","article-title":"The reversal of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with Amantadine","volume":"6","author":"Li","year":"2016","journal-title":"RSC Adv."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"24385","DOI":"10.1021\/acsami.6b06613","article-title":"Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways","volume":"8","author":"Li","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1039\/C6RA25010F","article-title":"The inhibition of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with zanamivir","volume":"7","author":"Lin","year":"2017","journal-title":"RSC Adv."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1021\/nn402062f","article-title":"Inhibition of Influenza A Virus Infection in Vitro by Saliphenylhalamide-Loaded Porous Silicon Nanoparticles","volume":"7","author":"Bimbo","year":"2013","journal-title":"ACS Nano"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Chakravarty, M., and Vora, A. (2020). Nanotechnology-based antiviral therapeutics. Drug Deliv. Transl. Res.","DOI":"10.1007\/s13346-020-00818-0"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/1040841X.2013.879849","article-title":"Metal nanoparticles: The protective nanoshield against virus infection","volume":"42","author":"Rai","year":"2016","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nmat5053","article-title":"Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism","volume":"17","author":"Cagno","year":"2018","journal-title":"Nat. Mater."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.tibtech.2018.06.003","article-title":"A Status Report on FDA Approval of Medical Devices Containing Nanostructured Materials","volume":"37","author":"Jones","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Cojocaru, F.D., Botezat, D., Gardikiotis, I., Uritu, C.M., Dodi, G., Trandafir, L., Rezus, C., Rezus, E., Tamba, B.I., and Mihai, C.T. (2020). Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020171"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"105465","DOI":"10.1016\/j.ejps.2020.105465","article-title":"A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection","volume":"153","author":"Ismail","year":"2020","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/12\/1020\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:03Z","timestamp":1760179263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/12\/1020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":150,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["pathogens9121020"],"URL":"https:\/\/doi.org\/10.3390\/pathogens9121020","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}